Please login to the form below

Not currently logged in
Email:
Password:

Orphan drugs and rare diseases

This page shows the latest Orphan drugs and rare diseases news and features for those working in and with pharma, biotech and healthcare.

PMEA 2018: celebrating excellence in improving patient outcomes

PMEA 2018: celebrating excellence in improving patient outcomes

AbbVie also took home two other awards, Excellence in Healthcare Professional Education Support Programmes (with support from Sciterion) and Excellence in Rare Diseases and Orphan Drugs (with support from Lucid). ... Meanwhile, for AbbVie’s and

Latest news

  • Orphan drugs from Biogen and Amicus win UK Prix Galien Orphan drugs from Biogen and Amicus win UK Prix Galien

    There was a much warmer welcome at the awards, hosted by ValueBase, for the pharma and biotech companies with products on the shortlist, which was dominated by orphan medicines. ... All bar one of the finalists were medicines for orphan conditions, and

  • Malthus’ orphans Malthus’ orphans

    By and large, rare diseases and orphan drugs don’t lend themselves to the former or the latter. ... Failure to apply some cold-hearted cost-benefit analysis to orphan drugs, rare diseases and other niches would inevitably lead to the ‘lower

  • Lucid picks up rare disease and orphan drugs trophy at PMEA 2017 Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

    Judges praised the AbbVie project for its impressive reach. Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted ... Narrowly missing first place, but still achieving a highly

  • Celgene scoops Socially Responsible Initiative prize at PMEA 2016 Celgene scoops Socially Responsible Initiative prize at PMEA 2016

    The objectives were laudable and the implementation made a big difference to many children's lives.”. ... Celgene was also a finalist with '75 Not Out' in the Rare Diseases and Orphan Drugs group.

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    Creates world leading rare diseases specialist. Shire has finalised its $32bn merger with Baxalta, creating one of the world's leading firms specialising in rare diseases and conditions. ... Shire now has over 50 rare diseases programmes in various

More from news
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • A rare talent A rare talent

    Change has also been the order of the day at Shire, with the Dublin-headquartered company taking strides towards future growth over the last couple of years, with rare diseases and ... A rare challenge. That knowledge is currently focused on bringing new

  • Reaching new heights Reaching new heights

    for rare diseases and technology-enabled changes in care that can harness big data to better inform decisions, help drive patient behaviour changes and improve outcomes. ... biologics. Patients will have greater access to breakthrough therapies and

  • Applying real-world evidence to orphan drugs Applying real-world evidence to orphan drugs

    This is particularly challenging in the area of rare diseases, in which there have been substantial advances, largely due to our increased knowledge of the genomic and biological makeup of the ... In Europe, the EU Committee of Experts on Rare Diseases

  • Another lost decade for research? Another lost decade for research?

    What does the patent landscape look like for antibiotics, vaccines and orphan drugs? ... The annual number of patent families filed in the field of rare diseases is far higher than for vaccines or antibiotics.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    What role can pharma play? The pharmaceutical industry is undergoing a transformative approach to rare diseases, as orphan drugs address a high unmet medical need and have been proven to be ... This article was originally published in the PME supplement

More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics